China · Delayed Price · Currency is CNY Enwei Pharmaceutical Statistics
Total Valuation
SHE:301331 has a market cap or net worth of CNY 2.62 billion. The enterprise value is 2.33 billion.
| Market Cap | 2.62B |
| Enterprise Value | 2.33B |
Important Dates
The last earnings date was Monday, April 27, 2026.
| Earnings Date | Apr 27, 2026 |
| Ex-Dividend Date | Jan 8, 2026 |
Share Statistics
SHE:301331 has 101.88 million shares outstanding. The number of shares has increased by 3.34% in one year.
| Current Share Class | 101.88M |
| Shares Outstanding | 101.88M |
| Shares Change (YoY) | +3.34% |
| Shares Change (QoQ) | -8.20% |
| Owned by Insiders (%) | 1.26% |
| Owned by Institutions (%) | 3.31% |
| Float | 29.87M |
Valuation Ratios
The trailing PE ratio is 55.39.
| PE Ratio | 55.39 |
| Forward PE | n/a |
| PS Ratio | 2.97 |
| PB Ratio | 2.41 |
| P/TBV Ratio | 3.00 |
| P/FCF Ratio | 106.48 |
| P/OCF Ratio | 32.13 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.25, with an EV/FCF ratio of 94.80.
| EV / Earnings | 48.38 |
| EV / Sales | 2.65 |
| EV / EBITDA | 22.25 |
| EV / EBIT | 40.89 |
| EV / FCF | 94.80 |
Financial Position
The company has a current ratio of 2.36, with a Debt / Equity ratio of 0.17.
| Current Ratio | 2.36 |
| Quick Ratio | 1.95 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 1.80 |
| Debt / FCF | 7.65 |
| Interest Coverage | 24.65 |
Financial Efficiency
Return on equity (ROE) is 4.45% and return on invested capital (ROIC) is 5.98%.
| Return on Equity (ROE) | 4.45% |
| Return on Assets (ROA) | 2.38% |
| Return on Invested Capital (ROIC) | 5.98% |
| Return on Capital Employed (ROCE) | 5.14% |
| Weighted Average Cost of Capital (WACC) | 7.16% |
| Revenue Per Employee | 586,010 |
| Profits Per Employee | 32,075 |
| Employee Count | 1,548 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 3.50 |
Taxes
In the past 12 months, SHE:301331 has paid 11.92 million in taxes.
| Income Tax | 11.92M |
| Effective Tax Rate | 19.84% |
Stock Price Statistics
The stock price has decreased by -3.13% in the last 52 weeks. The beta is 0.61, so SHE:301331's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -3.13% |
| 50-Day Moving Average | 26.66 |
| 200-Day Moving Average | 30.11 |
| Relative Strength Index (RSI) | 39.30 |
| Average Volume (20 Days) | 1,159,501 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SHE:301331 had revenue of CNY 879.60 million and earned 48.14 million in profits. Earnings per share was 0.46.
| Revenue | 879.60M |
| Gross Profit | 450.47M |
| Operating Income | 56.96M |
| Pretax Income | 60.06M |
| Net Income | 48.14M |
| EBITDA | 103.36M |
| EBIT | 56.96M |
| Earnings Per Share (EPS) | 0.46 |
Balance Sheet
The company has 474.81 million in cash and 187.90 million in debt, with a net cash position of 286.91 million or 2.82 per share.
| Cash & Cash Equivalents | 474.81M |
| Total Debt | 187.90M |
| Net Cash | 286.91M |
| Net Cash Per Share | 2.82 |
| Equity (Book Value) | 1.09B |
| Book Value Per Share | 10.55 |
| Working Capital | 529.76M |
Cash Flow
In the last 12 months, operating cash flow was 81.42 million and capital expenditures -56.85 million, giving a free cash flow of 24.57 million.
| Operating Cash Flow | 81.42M |
| Capital Expenditures | -56.85M |
| Depreciation & Amortization | 46.40M |
| Net Borrowing | -11.69M |
| Free Cash Flow | 24.57M |
| FCF Per Share | 0.24 |
Margins
Gross margin is 51.21%, with operating and profit margins of 6.48% and 5.47%.
| Gross Margin | 51.21% |
| Operating Margin | 6.48% |
| Pretax Margin | 6.83% |
| Profit Margin | 5.47% |
| EBITDA Margin | 11.75% |
| EBIT Margin | 6.48% |
| FCF Margin | 2.79% |
Dividends & Yields
This stock pays an annual dividend of 0.66, which amounts to a dividend yield of 2.49%.
| Dividend Per Share | 0.66 |
| Dividend Yield | 2.49% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 118.39% |
| Buyback Yield | -3.34% |
| Shareholder Yield | -0.86% |
| Earnings Yield | 1.84% |
| FCF Yield | 0.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 23, 2024. It was a forward split with a ratio of 1.48.
| Last Split Date | May 23, 2024 |
| Split Type | Forward |
| Split Ratio | 1.48 |
Scores
SHE:301331 has an Altman Z-Score of 5.93 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.93 |
| Piotroski F-Score | 5 |